Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ppul.22890 http://scihub22266oqcxt.onion/10.1002/ppul.22890 C4079258!4079258!24019259     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pediatr+Pulmonol 2014 ; 49 (7): 650-8 Nephropedia Template TP {{tp|p=24019259|t=2014. ANTI-PCRV ANTIBODY IN CYSTIC FIBROSIS: A NOVEL APPROACH TARGETING PSEUDOMONAS AERUGINOSA AIRWAY INFECTION |pdf=|usr=}}{{24019259}} gab.com Text ANTI-PCRV ANTIBODY IN CYSTIC FIBROSIS: A NOVEL APPROACH TARGETING PSEUDOMONAS AERUGINOSA AIRWAY INFECTION JO: Pediatr Pulmonol http://www.kidney.de/pget.php?&tw=1&pmid=24019259 #FOAvip Pseudomonas aeruginosa (Pa) airway infection is associated with increased morbidity and mortality in cystic fibrosis (CF). The type III secretion system is one of the factors responsible for the increased virulence and pro-inflammatory effects of Pa. KB001 is a PEGylated, recombinant, anti-Pseudomonas-PcrV antibody Fab? fragment that blocks the function of Pa TTSS. We studied the safety, pharmacokinetic (PK), and pharmacodynamic properties of KB001 in CF subjects with chronic Pa infection. Twenty-seven eligible CF subjects (? 12 years of age, FEV1 ? 40% of predicted, and sputum Pa density >105 CFU/gm) received a single intravenous dose of KB001 (3 mg/kg or 10 mg/kg) or placebo. Safety, PK, Pa density, clinical outcomes and inflammatory markers were assessed. KB001 had an acceptable safety profile and a mean serum half-life of 11.9 days. All subjects had Pa TTSS expression in sputum. There were no significant differences between KB001 and placebo for changes in Pa density, symptoms, or spirometry after a single dose. However, compared to baseline, at Day 28 there was a trend towards a dose-dependent reduction in sputum myeloperoxidase, IL-1, and IL-8, and there were significant overall differences in change in sputum neutrophil elastase and neutrophil counts favoring the KB001 10 mg/kg group versus placebo (?0.61 log10 and ?0.63 log10 respectively; p<0.05). These results support targeting Pa TTSS with KB001 as a non-antibiotic strategy to reduce airway inflammation and damage in CF patients with chronic Pa infection. Repeat-dosing studies are necessary to evaluate the durability of the anti-inflammatory effects and how that may translate into clinical benefit. (NCT00638365) Twit Text FOAVip ANTI-PCRV ANTIBODY IN CYSTIC FIBROSIS: A NOVEL APPROACH TARGETING PSEUDOMONAS AERUGINOSA AIRWAY INFECTION ????Pediatr Pulmonol http://www.kidney.de/pget.php?&tw=1&pmid=24019259 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24019259 #FOAvip English Wikipedia <ref>{{Cite pmid|24019259}}</ref> ANTI-PCRV ANTIBODY IN CYSTIC FIBROSIS: A NOVEL APPROACH TARGETING PSEUDOMONAS AERUGINOSA AIRWAY INFECTION #MMPMID24019259 Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE Pediatr Pulmonol 2014[Jul]; 49 (7): 650-8 PMID24019259show ga Pseudomonas aeruginosa (Pa) airway infection is associated with increased morbidity and mortality in cystic fibrosis (CF). The type III secretion system is one of the factors responsible for the increased virulence and pro-inflammatory effects of Pa. KB001 is a PEGylated, recombinant, anti-Pseudomonas-PcrV antibody Fab? fragment that blocks the function of Pa TTSS. We studied the safety, pharmacokinetic (PK), and pharmacodynamic properties of KB001 in CF subjects with chronic Pa infection. Twenty-seven eligible CF subjects (? 12 years of age, FEV1 ? 40% of predicted, and sputum Pa density >105 CFU/gm) received a single intravenous dose of KB001 (3 mg/kg or 10 mg/kg) or placebo. Safety, PK, Pa density, clinical outcomes and inflammatory markers were assessed. KB001 had an acceptable safety profile and a mean serum half-life of 11.9 days. All subjects had Pa TTSS expression in sputum. There were no significant differences between KB001 and placebo for changes in Pa density, symptoms, or spirometry after a single dose. However, compared to baseline, at Day 28 there was a trend towards a dose-dependent reduction in sputum myeloperoxidase, IL-1, and IL-8, and there were significant overall differences in change in sputum neutrophil elastase and neutrophil counts favoring the KB001 10 mg/kg group versus placebo (?0.61 log10 and ?0.63 log10 respectively; p<0.05). These results support targeting Pa TTSS with KB001 as a non-antibiotic strategy to reduce airway inflammation and damage in CF patients with chronic Pa infection. Repeat-dosing studies are necessary to evaluate the durability of the anti-inflammatory effects and how that may translate into clinical benefit. (NCT00638365) äANTI-PCRV ANTIBODY IN CYSTIC FIBROSIS: A NOVEL APPROACH TARGETING PSEU(epmc).pdf DeepDyve Pubget Overpricing